Acadian Asset Management
BIOL

Acadian Asset Management’s Biolase, Inc. BIOL Stock Holding History

Acadian Asset Management’s Portfolio BIOL Stock Details BIOL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-9,617
Closed -$67K – 1900
2023
Q2 		$67K Buy
+9,617
New +$161K ﹤0.01% 1482
2022
Q1 		– Sell
-32
Closed -$31K – 1856
2021
Q4 		$31K Buy
+32
New +$40.4K ﹤0.01% 1556

Other funds holding BIOL

AFM
Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Walleye Capital
Walleye Capital New York $24B AUM 37.67% 1-Year Est. Return
ZF
Zhang Financial Portage, Michigan $2.89B AUM 18.44% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $27.8B AUM 31.66% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Acadian Asset Management's BIOL Position: Q3 2023 in Review

Acadian Asset Management sold out of Biolase, Inc. (BIOL) in Q3 2023, closing a stake of 9,617 shares — an estimated $67K sold.

Acadian Asset Management first reported a position in BIOL in Q4 2021 and held it in 2 quarters. The position peaked at $67K in Q2 2023. 12 funds tracked by Wall St. Rank hold BIOL as of Q3 2023.

  • Acadian Asset Management reported no remaining Biolase, Inc. position as of Q3 2023 after selling out during the quarter.
  • Acadian Asset Management sold 9,617 Biolase, Inc. shares in Q3 2023, an estimated $67K.
  • Acadian Asset Management first reported a position in Biolase, Inc. in Q4 2021 and held it in 2 quarters.
  • Acadian Asset Management's Biolase, Inc. position peaked at $67K in Q2 2023.
  • 12 funds tracked by Wall St. Rank held Biolase, Inc. as of Q3 2023.

Based on Acadian Asset Management's 13F filing for Q3 2023, filed 13 Nov 2023.